Valves for the Pharmaceutical and Fine Chemical Industries Table of Contents Page Overview 3 Disc Bottom Outlet Valves Stainless Steel, Hastelloy and other Alloys 4 Glass/PTFE/PFA-lined Body 6 Additional Sensor Options - Temperature Sensors, Lining Integrity Monitoring 9 Ram Bottom Outlet Valves Stainless Steel, Hastelloy and other Alloys 10 Bottom Outlet Valves with Integrated Sampling Systems 11 Process Analytical Technology (PAT) in SchuF Valves 12 Case Study: SchuF MultiProbeTM Valve- Bespoke PAT 15 Case Study: Pharmaceutical Valve with PAT & Filtration Function 16 Customer Enquiry Form 18 Product Portfolio Overview 19 SchuF is fully registered, accredited and certified worldwide 2 Valves for the Pharmaceutical and Fine Chemical Industries Overview In recent years, the dual pressures of rationalisation and safety/environmental regulations have driven technical progress in the pharmaceutical and fine chemical industries, resulting in a number of significant developments.
refid# 2R20KQn53ZNg9QVgEZQe2rp1a20 pages
PlasticsEurope Fluoropolymer Products Group (FPG) Socioeconomic Impact Assessment for fluoropolymers FPG response to the PFAS draft restriction proposal 15 September 2023 SOCIOECONOMIC IMPACT ASSESSMENT FOR FLUOROPOLYMERS FPG response to the PFAS draft restriction proposal CONTENTS 1.
refid# ypZ5o1M3L6nvobz84kp78OERX52 pages
September 2023 AGC's CONTRIBUTION TO THE CONSULTATION ON THE RESTRICTION PROPOSAL ON PFAS AS REGARDS GENERAL COMMENTS AND GENERAL INFORMATION ON FLUOROPOLYMERS NON-CONFIDENTIAL Table of Contents Table of Contents ............................................................................................................1 Introduction ...................................................................................................................... 2 Part 1.
refid# 828exwwkaL3gpG3VpazoeOwGK37 pages
Aug 1, 2023 Comment on Proposed Restriction of PFAS Japan Valve Manufacturers' Association (JVMA) Japan Valve Manufacturers' Association (JVMA) appreciates the opportunity to provide comments to the PFAS restriction proposal. 1.
refid# wgDGL9KLMY0eb8w12Rxqjy62E4 pages
Assogomma comments on the Annex XV Dossier of the universal PFAS restriction proposal September, 6th 2023 1 1.
refid# 71ngzbE45jrBE188a6202joVa35 pages
Note 1.
refid# G84OYzYxxMOE03yXBkR6KrKv1 page
Company: REMBE Safety+Control GmbH (REMBE) Sector: process safety, explosion protection ECHA application for exemption for rupture discs containing PTFE, FEP or PFA: PFAS CAS-Nr.
refid# vVGvonnke95V9o4B6Ynderp6Z6 pages
Honeywell International Sarl Z.A.
refid# 3J3kzwM3dmOGoOm72aBLRMRO14 pages
Your ref: Our ref: CS/HPR Date: 22th of September 2023 Restriction of per- and poly-fluoroalkyl substances (PFAS) under REACH The Federation of Norwegian Industries represents more than 3200 companies with approx. 127,500 employees.
refid# rppXeqerJkkgomBZo6Z4n7J5e3 pages
Statement on the potential PFAS ban Date: 22 September 2023 Would ARBURG be affected by the potential PFAS ban?
refid# ErDJmjbRp852Yb36Y9YMmmyL2 pages
Application Number: E2.10_transortation applications Fluororesin used: PTFE (CAS No. 9002-84-0) Product Overview: Valve seats and the like Fluororesin is used in the automotive industry as valve seats for solenoid valves in engine compartments in transportation applications.
refid# 4J59g04pEomZLK349Qz10N30V2 pages
Proposed REACH restriction on PFAS Comments Confindustria September 2023 Date - Year 1.
refid# 2jVrMmObjvbKQ7N19349NoNmN35 pages
Lab Isla L 1538 NOTICE SBRTC-2015-1052-7 I.
refid# qaGnEbx0j6LGV8D7qB5QraQDR9 pages
The data below is taken from two Flowserve publications, (i) Guide to the Selection of Corrosion Resisting Alloys and (ii) Guide to the Selection of Corrosion Resisting Non-Metallics.
refid# MGJQzrvQJpj0EoGmbXMmgYzQj1 page
EUROPEAN MEDICINES AGENCY SCIENCE MEDICINES HEALTH 1 30 March 2023 2 EMA/CHMP/83033/2023 3 Committee for Medicinal Products for Human Use (CHMP) 4 Questions and answers on data requirements when 5 replacing hydrofluorocarbons as propellants in oral 6 pressurised metered dose inhalers 7 8 Agreed by Rheumatology and Immunology Working Party February 2023 Adopted by CHMP for release for consultation 30 Mar 2023 Start of public consultation April 2023 End of consultation (deadline for comments) 9 10 31 May 2023 Comments should be provided using this template.
refid# zdKRE0RKp4J1v6VjG2KowmbX69 pages